Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.66%0700.HK-6.20%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.05%ORCL-0.97%3988.HK-0.44%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.65%0857.HK-1.46%UNH-10.21%1288.HK-1.42%PM-0.85%0005.HK-2.16%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.68%AUDUSD-1.57%AUDCAD-1.00%EURAUD+0.99%AUDCHF-0.98%GBPAUD+0.91%AUDNZD-0.87%NZDJPY-0.83%GBPJPY-0.78%EURJPY-0.73%CHFJPY-0.70%CADJPY-0.70%NZDUSD-0.70%GBPUSD-0.65%USDCHF+0.62%AUDSGD-0.62%EURUSD-0.60%USDCAD+0.59%AUDDKK-0.54%USDZAR+0.47%USDMXN+0.42%GBPTRY+0.41%USDTHB+0.39%AUDNOK-0.37%USDNOK+0.33%GBPHKD+0.32%EURZAR+0.31%NZDMXN+0.30%GBPMXN-0.28%GBPZAR+0.28%CHFNOK+0.26%NOKJPY-0.25%USDSEK+0.24%USDPLN+0.21%USDTRY+0.21%EURCNH-0.19%EURNOK+0.19%EURHKD-0.17%CHFSEK+0.16%USDILS+0.16%USDDKK+0.16%USDJPY-0.14%NZDCAD-0.13%PLNJPY-0.12%USDCNH-0.12%GBPSGD-0.11%NZDCHF-0.11%EURNZD+0.10%EURSGD-0.08%EURSEK+0.08%GBPCAD-0.08%USDSGD+0.07%EURGBP+0.06%GBPNZD+0.05%EURPLN+0.05%EURCZK+0.04%USDCOP-0.04%GBPCHF-0.03%CADCHF+0.03%EURCHF+0.02%SGDJPY+0.02%USDHKD-0.02%NZDSGD-0.02%EURCAD-0.01%CHFSGD0.00%EURDKK0.00%XPTUSD-1.21%XAGUSD-0.81%GAGUSD-0.81%W1-0.62%HG1-0.60%XAUUSD-0.51%GAUUSD-0.51%C1-0.46%XNGUSD-0.38%S1-0.25%UKOIL+0.16%USOIL-0.10%BTCUSD-3.54%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.74%ZECUSDT-6.89%XMRUSDT-2.10%DOGEUSD+55.95%LINKUSD-3.33%XLMUSD-3.84%BCHUSDT-3.55%LTCUSD+47.50%UNIUSD-3.16%SUIUSD-2.99%TONUSD+59.18%HBARUSDT-5.19%TAOUSDT-3.19%AAVEUSD-3.38%ONDOUSDT-5.32%ICPUSDT-2.18%DOTUSDT-3.76%WLDUSDT-3.57%ARBUSDT-5.60%ATOMUSDT-2.39%INJUSDT-7.45%STXUSDT-3.46%PYTHUSDT-0.81%TIAUSDT-3.10%FETUSDT-4.61%JUPUSDT+0.25%SEIUSDT-4.48%GRTUSDT-3.22%OPUSDT-3.90%IOTAUSDT-2.52%POLUSDT-2.08%WIFUSDT-2.98%AXSUSDT-3.05%EOSUSDT-4.31%IMXUSDT-3.36%FARTCOINUSDT-6.94%GALAUSDT-2.38%DYDXUSDT-2.85%ORDIUSDT-2.64%NOTUSDT-2.34%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.66%0700.HK-6.20%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.05%ORCL-0.97%3988.HK-0.44%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.65%0857.HK-1.46%UNH-10.21%1288.HK-1.42%PM-0.85%0005.HK-2.16%NVS-2.46%INTC-0.91%HSBA.L-2.00%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.68%AUDUSD-1.57%AUDCAD-1.00%EURAUD+0.99%AUDCHF-0.98%GBPAUD+0.91%AUDNZD-0.87%NZDJPY-0.83%GBPJPY-0.78%EURJPY-0.73%CHFJPY-0.70%CADJPY-0.70%NZDUSD-0.70%GBPUSD-0.65%USDCHF+0.62%AUDSGD-0.62%EURUSD-0.60%USDCAD+0.59%AUDDKK-0.54%USDZAR+0.47%USDMXN+0.42%GBPTRY+0.41%USDTHB+0.39%AUDNOK-0.37%USDNOK+0.33%GBPHKD+0.32%EURZAR+0.31%NZDMXN+0.30%GBPMXN-0.28%GBPZAR+0.28%CHFNOK+0.26%NOKJPY-0.25%USDSEK+0.24%USDPLN+0.21%USDTRY+0.21%EURCNH-0.19%EURNOK+0.19%EURHKD-0.17%CHFSEK+0.16%USDILS+0.16%USDDKK+0.16%USDJPY-0.14%NZDCAD-0.13%PLNJPY-0.12%USDCNH-0.12%GBPSGD-0.11%NZDCHF-0.11%EURNZD+0.10%EURSGD-0.08%EURSEK+0.08%GBPCAD-0.08%USDSGD+0.07%EURGBP+0.06%GBPNZD+0.05%EURPLN+0.05%EURCZK+0.04%USDCOP-0.04%GBPCHF-0.03%CADCHF+0.03%EURCHF+0.02%SGDJPY+0.02%USDHKD-0.02%NZDSGD-0.02%EURCAD-0.01%CHFSGD0.00%EURDKK0.00%XPTUSD-1.21%XAGUSD-0.81%GAGUSD-0.81%W1-0.62%HG1-0.60%XAUUSD-0.51%GAUUSD-0.51%C1-0.46%XNGUSD-0.38%S1-0.25%UKOIL+0.16%USOIL-0.10%BTCUSD-3.54%ETHUSD+57.77%USDTUSD-0.01%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.74%ZECUSDT-6.89%XMRUSDT-2.10%DOGEUSD+55.95%LINKUSD-3.33%XLMUSD-3.84%BCHUSDT-3.55%LTCUSD+47.50%UNIUSD-3.16%SUIUSD-2.99%TONUSD+59.18%HBARUSDT-5.19%TAOUSDT-3.19%AAVEUSD-3.38%ONDOUSDT-5.32%ICPUSDT-2.18%DOTUSDT-3.76%WLDUSDT-3.57%ARBUSDT-5.60%ATOMUSDT-2.39%INJUSDT-7.45%STXUSDT-3.46%PYTHUSDT-0.81%TIAUSDT-3.10%FETUSDT-4.61%JUPUSDT+0.25%SEIUSDT-4.48%GRTUSDT-3.22%OPUSDT-3.90%IOTAUSDT-2.52%POLUSDT-2.08%WIFUSDT-2.98%AXSUSDT-3.05%EOSUSDT-4.31%IMXUSDT-3.36%FARTCOINUSDT-6.94%GALAUSDT-2.38%DYDXUSDT-2.85%ORDIUSDT-2.64%NOTUSDT-2.34%RONINUSDT-2.92%

Erasca, BMS in ERAS-0015 cancer trial pact

NEWS

November 18, 2026 at 01:41 UTC

3 min read
Biomedical researcher at a microscope symbolizing the ERAS-0015 cancer trial collaboration for ERAS and BMS

Key Points

  • 01Erasca and Bristol Myers Squibb agreed a clinical trial collaboration for ERAS-0015
  • 02Planned Phase 1/2 trial will test ERAS-0015 with navlimetostat in MTAP-deleted PDAC
  • 03Bristol Myers Squibb will sponsor the study while Erasca supplies ERAS-0015
  • 04Both companies retain development and commercial rights to their own drugs

Erasca and Bristol Myers Squibb launch ERAS-0015 trial collaboration

Erasca has entered a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate ERAS-0015 in combination with navlimetostat in pancreatic cancer. The collaboration focuses on a planned Phase 1/2 study in patients with MTAP-deleted pancreatic ductal adenocarcinoma. Under the agreement, Bristol Myers Squibb will sponsor the trial, and Erasca will provide its investigational drug ERAS-0015. The arrangement is structured as a mutually non-exclusive agreement, with each company retaining development and commercial rights to its respective compound.

Design and focus of the planned Phase 1/2 study

The Phase 1/2 trial will evaluate ERAS-0015, described as a potentially best-in-class pan-RAS molecular glue, together with navlimetostat, Bristol Myers Squibb’s investigational PRMT5 inhibitor also known as BMS-986504. The study will enroll patients with MTAP-deleted pancreatic ductal adenocarcinoma, a molecularly defined subset of pancreatic cancer. ERAS-0015 will be supplied by Erasca, while navlimetostat will be provided under Bristol Myers Squibb’s sponsorship of the trial. The planned study is designed to investigate the combination regimen rather than to establish a demonstrated treatment benefit at this stage.

Erasca has described ERAS-0015 as an investigational, oral pan-RAS molecular glue intended to inhibit RAS signaling in cancer. Navlimetostat is characterized as an investigational PRMT5 inhibitor being developed by Bristol Myers Squibb. By pairing these two agents, the trial will assess the impact of dual targeting of RAS and PRMT5 pathways in patients whose tumors have MTAP deletions. Nearly all MTAP-deleted pancreatic cancers are reported to harbor co-occurring RAS mutations, which provides a rationale for exploring this combination in this patient population.

Strategic aims and scientific rationale

The collaboration is intended to leverage the complementary mechanisms of ERAS-0015 and navlimetostat in MTAP-deleted pancreatic cancer. Erasca has indicated that the combination could potentially enhance antitumor activity through simultaneous inhibition of RAS and PRMT5. Because nearly all MTAP-deleted pancreatic cancers have co-occurring RAS mutations, this approach targets both a genetic driver and a pathway vulnerability associated with MTAP loss. The trial will further explore the role of ERAS-0015 as a possible treatment backbone in RAS-driven cancers when used in combination regimens.

Early results from ERAS-0015 in separate clinical work, such as the AURORAS-1 trial, have shown favorable safety and tolerability, with evidence of partial responses in multiple patients. These data have contributed to interest in expanding evaluation of ERAS-0015 into combination studies, including with navlimetostat in MTAP-deleted pancreatic ductal adenocarcinoma. However, the therapeutic potential of the ERAS-0015 and navlimetostat combination remains to be established in the planned Phase 1/2 trial. The collaboration leaves both parties free to pursue additional development paths, consistent with the mutually non-exclusive nature of the agreement.

Key Takeaways

  • 01The agreement formalizes a structured collaboration where Bristol Myers Squibb sponsors the trial and Erasca supplies ERAS-0015 while keeping its own development flexibility.
  • 02The study concentrates on MTAP-deleted pancreatic ductal adenocarcinoma, a defined molecular subset that aligns with the mechanisms of RAS and PRMT5 inhibition.
  • 03Existing ERAS-0015 data from other studies support continued clinical exploration, but the efficacy of its combination with navlimetostat will depend on outcomes from this new Phase 1/2 trial.

Erasca, BMS in ERAS-0015 cancer trial pact | Trading Dashboard